Bristol Myers Squibb Q3 FY25: where the revenue came from and where it went
The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Oct 30, 2025
Revenue$12.22B
+3% year over year
Gross profit$8.79B
72% margin
Operating profit−$1.03B
−8% margin
Net profit$2.20B
18% margin
Net profit is larger than what operations earned, because the statement adds $4.15B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 12.22 | 100% | +3% |
| Growth portfolio | 6.86 | 56% | +18% |
| Eliquis | 3.75 | 31% | +25% |
| Pomalyst/Imnovid | 0.68 | 5% | −25% |
| Revlimid | 0.58 | 5% | −59% |
| Other legacy products | 0.18 | 1% | −21% |
| Sprycel | 0.12 | 1% | −59% |
| Abraxane | 0.07 | 1% | −71% |
| Cost of revenue | −3.44 | 28% | |
| Gross profit | 8.79 | 72% margin | −3pp |
| R&D | −2.53 | 21% | +1pp |
| SG&A | −1.79 | 14% | −2pp |
| Other | −5.50 | 45% | +0pp |
| Operating profit | −1.03 | −8% margin | +0pp |
| Other income, net | 4.15 | ||
| Tax | −0.92 | ||
| Net profit | 2.20 | 18% margin | +8pp |
220 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest